Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents

OBJECTIVES: Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability of antiviral drugs, particularly relevant in patients with advanced liver disease caused by chronic hepatitis C virus (HCV) infection seeking therapy. Using integrated dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiffman, Mitchell L, Rustgi, Vinod, Bennett, Michael, Forns, Xavier, Asselah, Tarik, Planas Vila, Ramon, Liu, Li, Pedrosa, Marcos, Moller, Jonathan, Reau, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Liver
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897007/
https://www.ncbi.nlm.nih.gov/pubmed/27045929
http://dx.doi.org/10.1038/ajg.2016.108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897007/
https://www.ncbi.nlm.nih.gov/pubmed/27045929
http://dx.doi.org/10.1038/ajg.2016.108

Ejemplares similares